Long-Term Investor Stock Analysis of Bristol Myers Squibb (BMY)Read More »
This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Long-Term Investor Stock Analysis of Bristol Myers Squibb (BMY)
Views: 217 Date: 2026-01-24 Bristol Myers Squibb is a global biopharmaceutical company focused on oncology, immunology, cardiovascular disease, and hematology. It generates revenue by developing, manufacturing, and commercializing patented prescription drugs, with cash flows heavily dependent on a small number of blockbuster therapies. The business benefits from high gross margins and strong pricing power during patent exclusivity, but faces structural risks from patent expirations, regulatory pressure, and capital intensity. Growth increasingly relies on acquisitions rather than organic innovation, raising questions about long-term return on invested capital. Investment Goal: My goal is to earn an average of at least 9% per …
